» Articles » PMID: 11097055

The Interaction of Drugs with DNA Gyrase: a Model for the Molecular Basis of Quinolone Action

Overview
Specialty Biochemistry
Date 2000 Nov 30
PMID 11097055
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

DNA gyrase supercoils DNA in bacteria. The fact that it is essential in all bacteria and absent from eukaryotes makes it an ideal drug target. We discuss the action of coumarin and quinolone drugs on gyrase. In the case of coumarins, the drugs are known to be competitive inhibitors of the gyrase ATPase reaction. From a combination of structural and biochemical studies, the molecular details of the gyrase-coumarin complex are well established. In the case of quinolones, the drugs are thought to act by stabilising a cleavage complex between gyrase and DNA that arrests polymerases in vivo. The exact nature of the gyrase-quinolone-DNA complex is not known; we propose a model for this complex based on structural and biochemical data.

Citing Articles

Novel Fluoroquinolones with Possible Antibacterial Activity in Gram-Negative Resistant Pathogens: In Silico Drug Discovery.

Coba-Males M, Lavecchia M, Alcivar-Leon C, Santamaria-Aguirre J Molecules. 2023; 28(19).

PMID: 37836772 PMC: 10574177. DOI: 10.3390/molecules28196929.


DNA Gyrase as a Target for Quinolones.

Spencer A, Panda S Biomedicines. 2023; 11(2).

PMID: 36830908 PMC: 9953508. DOI: 10.3390/biomedicines11020371.


Ter-Seq: A high-throughput method to stabilize transient ternary complexes and measure associated kinetics.

Chattopadhyay G, Ahmed S, Srilatha N, Asok A, Varadarajan R Protein Sci. 2022; 32(1):e4514.

PMID: 36382921 PMC: 9793979. DOI: 10.1002/pro.4514.


Heat Shock Protein 70 and 90 Family in Prostate Cancer.

Fu X, Liu J, Yan X, DiSanto M, Zhang X Life (Basel). 2022; 12(10).

PMID: 36294924 PMC: 9605364. DOI: 10.3390/life12101489.


New Life of an Old Drug: Caffeine as a Modulator of Antibacterial Activity of Commonly Used Antibiotics.

Woziwodzka A, Krychowiak-Masnicka M, Golunski G, Losiewska A, Borowik A, Wyrzykowski D Pharmaceuticals (Basel). 2022; 15(7).

PMID: 35890171 PMC: 9315996. DOI: 10.3390/ph15070872.